Why Is Athira Pharma Inventory Plunging On Wednesday? – Athira Pharma (NASDAQ:ATHA)

On Wednesday, Athira Pharma, Inc. ATHA inventory is buying and selling decrease after the corporate launched topline outcomes from its Part 2/3 LIFT-AD scientific trial of fosgonimeton for mild-to-moderate Alzheimer’s illness (AD).

A -0.08 change in GST (the World Statistical Take a look at, a mix of outcomes from measures of cognition (ADAS-Cog11) and performance (ADCS-ADL23) favoring fosgonimeton that didn’t attain statistical significance (p=0.70) 

The change in cognition from baseline, for which a lower from baseline represents an enchancment, was -0.39 for the placebo group and -1.09 for the fosgonimeton-treated group, a distinction of -0.70 (p=0.35) favoring fosgonimeton.

Within the fosgonimeton-treated group, perform elevated (improved) by 0.65 versus a decline of -0.02 in placebo, though this distinction didn’t meet statistical significance (p=0.61).

As well as, knowledge throughout protein pathology, irritation, and neurodegeneration biomarkers confirmed directional enhancements with fosgonimeton therapy.

“These should not the outcomes we hoped for, as the dearth of scientific decline within the placebo group, mixed with the quick length of the examine, could have impacted the trial’s capacity to translate the impact of fosgonimeton therapy into significant scientific profit,” stated Javier San Martin, Chief Medical Officer of Athira.

In a subgroup of sufferers with extra superior illness, the analyses confirmed a higher numerical therapy impact in scientific outcomes within the fosgonimeton therapy group in comparison with placebo:

• The change in cognition confirmed the fosgonimeton therapy group (n=61) improved in comparison with placebo (n=70), with a delta of -1.16 (p=0.39).
• For AD sufferers who’re carriers of the APOE4 gene, the placebo group (n=74) declined in cognition as assessed by ADAS-Cog11 over the 26 weeks, whereas the fosgonimeton therapy group (n=74) remained steady, with a delta of -1.07 (p=0.33)

In put up hoc evaluation by illness severity, fosgonimeton confirmed a bigger impact dimension primarily pushed by improved cognition at week 26.

• Sufferers with the best baseline ADAS-Cog11 (>30) who had been handled with fosgonimeton (n=42) in comparison with placebo (n=52) confirmed a -2.51 enchancment in cognition (p=0.16), for which a decrease quantity represents an enchancment.
• A small subset of sufferers with reasonable dementia who had been handled with fosgonimeton (n=20) in comparison with placebo (n=19) confirmed a -3.74 enchancment in cognition (p=0.21).

Worth Motion: ATHA inventory was down 72.8% at $0.77 throughout the premarket session on the time of this writing on Wednesday.

Learn Subsequent: